The data showed high expression of CCR7 in tumor cells predicted lower Overall Survival (OS) of patients and knocking out CCR7 enhanced the sensitivity of HCC to sorafenib as a result of inhibiting EMT through the AKT and ERK signaling pathways. The gene discussed is CCR7; the disease is hepatocellular carcinoma.